← Back to Search

Monoclonal Antibodies

A Safety Study of LY3462817 and LY3509754 in Participants With Psoriasis

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through final follow-up (up to week 52 for ly3462817 & up to week 16 for ly3509754)

Summary

This trial is testing two new drugs, LY3462817 and LY3509754, to see if they are safe for people with psoriasis. Researchers will observe how the body processes these drugs. The study will last over a year for LY3462817 and a few months for LY3509754.

Eligible Conditions
  • Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through final follow-up (up to week 52 for ly3462817 & up to week 16 for ly3509754)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through final follow-up (up to week 52 for ly3462817 & up to week 16 for ly3509754) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to LY3462817 and LY3509754
Secondary study objectives
Pharmacokinetics (PK): Average Concentration (Cave) of LY3462817 and LY3509754

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3509754Experimental Treatment1 Intervention
LY3509754 administered orally.
Group II: LY3462817 - Subcutaneous (SC)Experimental Treatment1 Intervention
LY3462817 administered as SC injections. (SC administration is discretionary/optional.)
Group III: LY3462817 - Intravenous (IV)Experimental Treatment1 Intervention
LY3462817 administered as IV infusions.
Group IV: Placebo - SCPlacebo Group1 Intervention
Placebo administered as SC injections. (SC administration is discretionary/optional.)
Group V: Placebo - IVPlacebo Group1 Intervention
Placebo administered as IV infusions.
Group VI: PlaceboPlacebo Group1 Intervention
Placebo administered orally.

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,466,354 Total Patients Enrolled
37 Trials studying Psoriasis
20,623 Patients Enrolled for Psoriasis
Study DirectorEli Lilly and Company
1,391 Previous Clinical Trials
428,811 Total Patients Enrolled
31 Trials studying Psoriasis
10,506 Patients Enrolled for Psoriasis
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top